Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma

Journal of the Pancreas

Volumn 13, Issue 5, 2012, Pages 497-501

  Peddi, Parvin F ^a   Lubner, Sam ^d   McWilliams, Robert ^e   Tan, Benjamin R ^a   Picus, Joel ^a   Sorscher, Steven M ^a   Suresh, Rama ^a   Craig Lockhart, A ^a   Wang, Jian ^f   Menias, Christine ^b   Gao, Feng ^c   Linehan, David ^c   Wang Gillam, Andrea ^a  

^a Division of Oncology   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e MAYO CLINIC   (United States)

^f ZHENGZHOU UNIVERSITY   (China)

Author keywords

Adenocarcinoma; Adult; Antimetabolites; Antineoplastic adverse effects; Antineoplastic combined chemotherapy protocols adverse effects; Follow up studies; Granulocyte colony stimulating factor; Neoadjuvant therapy; Pancreatic neoplasms; Registries; Survival analysis; United States

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTINUOUS INFUSION; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERANCE; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ABDOMINAL PAIN; ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84866378244     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: A Cancer Journal for Clinicians. 2012; 62(1):10-29.
2. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15(6):2403-2413.
3. Di Marco M, Di Cicilia R, Macchini M, et al. Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review). Oncol Rep 2010; 23(5):1183-1192.
4. Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010; 28(22):3605-3610.
5. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010; 28(22):3617-3622.
6. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25(15):1960-1966.
7. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364(19):1817-1825.
8. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25(13):1670-1676.
9. DCTD, NCI, NIH, DHHS. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0. 2006. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
10. Assaf E, Verlinde-Carvalho M, Delbaldo C, et al. 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncology 2011; 80(5-6):301-306.
11. Hosein PJ, Macintyre J, Kawamura C, et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderlineresectable locally advanced pancreatic adenocarcinoma. BMC Cancer 2012; 12(1):199.
12. Howlader N, Noone A, Krapcho M, Neyman N, Aminou R. SEER Cancer Statistics Review 1975-2009 (Vintage 2009 Populations). Available at: http://seer.cancer.gov/csr/1975_2009_pops09/index.html. Accessed May 10, 2012.
13. Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011; 29(34):4548-4554.